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The poor performance of apps assessing skin cancer
risk
These apps are the product of inadequate evaluation and regulation
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Over the past year, technology companies have made headlines
claiming that their artificially intelligent (AI) products can
outperform clinicians at diagnosing breast cancer,1 brain
tumours,2 and diabetic retinopathy.3 Claims such as these have
influenced policy makers, and AI now forms a key component
of the national health strategies in England, the United States,
and China.
It is positive to see healthcare systems embracing data analytics
and machine learning. However, there are reasonable concerns
about the efficacy, ethics, and safety of some commercial, AI
health solutions.4 5 Trust in AI applications (or apps) heavily
relies on the myth of the objective and omniscient algorithm,
and our systems for generating and implementing evidence have
not yet met the new specific challenges of AI. They may even
have failed on the basics. In a linked article, Freeman and
colleagues6 (doi:10.1136/bmj.m127) throw these general
concerns into stark relief with a close examination of the
evidence on diagnostic apps for skin cancer.
Exposing inaccuracies
The authors report results from a systematic review of studies
evaluating the accuracy of smartphone apps that were offered
directly to the public for risk stratification of skin lesions. Nine
studies were included, evaluating a total of six apps. Even
though methodological decisions made by the instigators of the
studies probably led to overestimation of the apps’ real world
performance, Freeman and colleagues still found evidence for
accuracy to be lacking.
Some apps gave conflicting management advice for the same
lesions, and their recommendations were commonly inconsistent
with clinical histopathological results. In short, little evidence
indicates that current AI apps can beat clinicians when assessing
skin lesion risk, at least not in a verifiable or reproducible form.
Misleading regulation
Currently, two apps from the study are available in the UK.
Freeman and colleagues found no peer reviewed, published
studies evaluating the Teleskin skinScan app. The second,
SkinVision, when validated against expert recommendations
was found to be poor. Yet both are approved and regulated as
“class I medical devices”; and both have a CE mark.
This official approval will give consumers the impression that
the apps have been assessed as effective and safe. But “class I”
is the European classification for low risk devices, such as
plasters and reading glasses. The implicit assumption is that
apps are similarly low risk technology. But shortcomings in
diagnostic apps can have serious implications: for patients and
the public, risks include psychological harm from health anxiety
or “cyberchondria,” and physical harm from misdiagnosis or
overdiagnosis; for clinicians there is a risk of increased
workload, and changes to ethical or legal responsibilities around
triage, referral, diagnosis, and treatment; for the system, there
is a risk of inappropriate resource use, and even loss of
credibility for digital technology in general.
Doing better
The current regimen is clearly unsatisfactory. Collectively as a
society we must decide what amounts to good evidence when
evaluating health apps; who is responsible for generating,
validating, and appraising this evidence; and how post-market
monitoring of regularly updated software should be organised.
These are complex questions.
Regulators clearly have a role. We must decide which activities
they will regulate: risk stratification apps clearly perform a
medical function; “wellness” apps for meditation and
mindfulness are a grey area, but could nonetheless cause
psychological harm. Regulators most accustomed to managing
medicines will need new skills to evaluate digital technology.
But wherever the perimeter is drawn, they must avoid false
reassurance: when regulators are notevaluating technology, they
should clearly flag this to patients and policy makers.
Softer governance measures (eg, policies and standards) from
governing bodies such as NHS England, can facilitate the
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creation of rational and transparent markets. Clinicians, patients,
and commissioners are all potential customers for health apps.
Guidance, such as that recently produced by Public Health
England on evaluating digital health products,7 can help ensure
that they each know enough to require, find, understand,
critically evaluate, and apply good evidence, within reasonable
limits. This is likely to help drive better innovation, by rewarding
only products that deliver tangible benefits. Clinicians should
also be trained to evaluate the tools they recommend to patients,
avoid the pitfalls of automation bias, and identify the clinical
tasks that can be automated safely.
Lastly, we need a cultural shift. It must become the norm, or
social expectation, that all those developing health apps and AI
solutions support third party access to data, in a trustworthy
manner; and code, within the parameters of technical feasibility,
while respecting ownership of intellectual property. This would
facilitate competition, reproducibility, audit, and error
correction,8 driving up the overall quality of solutions available
on the market. It would also enable more independent real world
evaluations of market solutions to be conducted, provided that
funders are willing to support this type of research.
Collectively, these actions will improve evidence and
transparency across the whole algorithm lifecycle.9 10 Reliable
evaluations must find the truth, purchasers must require and use
those truths, and regulators and other governing bodies must
support and enhance these processes. Without better information
patients, clinicians, and other stakeholders cannot be assured
of an app’s efficacy, and safety.
Competing interests: We have read and understood BMJ policy on declaration of
interests. JM is a recent employee of NHSX, the governing body for digital, data,
and technology policy in the NHS, and has received a research grant from the
Digital Catapult in the past 12 months. Neither organisation has been involved in
the writing of this editorial.
Provenance and peer review: Commissioned; not peer reviewed.
1 McKinney SM, Sieniek M, Godbole V, etal . International evaluation of an AI system for
breast cancer screening. Nature 2020;577:89-94. 10.1038/s41586-019-1799-6 31894144
2 Hollon TC, Pandian B, Adapa AR, etal . Near real-time intraoperative brain tumor diagnosis
using stimulated Raman histology and deep neural networks. Nat Med 2020;26:52-8.
10.1038/s41591-019-0715-9 31907460
3 De Fauw J, Ledsam JR, Romera-Paredes B, etal . Clinically applicable deep learning for
diagnosis and referral in retinal disease. Nat Med 2018;24:1342-50.
10.1038/s41591-018-0107-6 30104768
4 Shaw J, Rudzicz F, Jamieson T, Goldfarb A. Artificial intelligence and the implementation
challenge. J Med Internet Res 2019;21:e13659. https://www.scopus.com/inward/record.
uri?eid=2-s2.0-85069551590&doi=10.2196%2f13659&partnerID=40&
md5=93d1414c9b5bc483b20ef58d9df41fb410.2196/13659 31293245
5 Van Calster B, Wynants L, Timmerman D, Steyerberg EW, Collins GS. Predictive analytics
in health care: how can we know it works?J Am Med Inform Assoc 2019;26:1651-4.
10.1093/jamia/ocz130 31373357
6 Freeman K, Dinnes J, Chuchu N, etal . Algorithm based smartphone apps to assess risk
of skin cancer in adults: systematic review of diagnostic accuracy studies. BMJ
2020;368:m127.
7 Public Health England. Evaluating digital health products. 2020. https://www.gov.uk/
government/collections/evaluating-digital-health-products
8 Goldacre B, Morton CE, DeVito NJ. Why researchers should share their analytic code.
BMJ 2019;367:l6365. 10.1136/bmj.l6365 31753846
9 Crawford K, Calo R. There is a blind spot in AI research. Nature 2016;538:311-3.
10.1038/538311a 27762391
10 Morley J, Floridi L, Kinsey L, Elhalal A. From what to how: an initial review of publicly
available AI ethics tools, methods and research to translate principles into practices. Sci
Eng Ethics 2019;10.1007/s11948-019-00165-5. 31828533
Published by the BMJ Publishing Group Limited. For permission to use (where not already
granted under a licence) please go to http://group.bmj.com/group/rights-licensing/
permissions
For personal use only: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2020;368:m428 doi: 10.1136/bmj.m428 (Published 10 February 2020) Page 2 of 2
EDITORIALS
 on 21 A
pril 2021 at B












J: first published as 10.1136/bm
j.m
428 on 10 F
ebruary 2020. D
ow
nloaded from
 
